Key Takeaways HAE delivered Q3 adjusted EPS of $1.31, up 10.1% y/y, while revenues fell 2.7% to $339M, yet beat estimates.HAE saw Plasma sales rise, while Blood Center and Hospital sales fell on order timing and portfolio cuts. Haemonetics expanded gross margin to 59.7% and operating margin to 23.3% as costs fell and profits rose. Haemonetics Corporation (HAE) delivered third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.31, which rose 10.1% year over year. The bottom line topped the Zacks Con ...